204 related articles for article (PubMed ID: 16609064)
61. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Witzig TE; Luigi Zinzani P; Habermann TM; Tuscano JM; Drach J; Ramchandren R; Kalayoglu Besisik S; Takeshita K; Casadebaig Bravo ML; Zhang L; Fu T; Goy A
Am J Hematol; 2017 Oct; 92(10):E575-E583. PubMed ID: 28699256
[TBL] [Abstract][Full Text] [Related]
62. Phase1/-2 study of Pomalidomide in myelofibrosis.
Mesa RA; Pardanani AD; Hussein K; Wu W; Schwager S; Litzow MR; Hogan WJ; Tefferi A
Am J Hematol; 2010 Feb; 85(2):129-30. PubMed ID: 20052748
[No Abstract] [Full Text] [Related]
63. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
[TBL] [Abstract][Full Text] [Related]
64. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
65. Lenalidomide is safe and active in Waldenström macroglobulinemia.
Fouquet G; Guidez S; Petillon MO; Louni C; Ohyba B; Dib M; Poulain S; Herbaux C; Martin A; Thielemans B; Brice P; Choquet S; Bakala J; Bories C; Demarquette H; Nudel M; Tournilhac O; Arnulf B; LeGouill S; Morel P; Banos A; Karlin L; Salles G; Leblond V; Leleu X
Am J Hematol; 2015 Nov; 90(11):1055-9. PubMed ID: 26284823
[TBL] [Abstract][Full Text] [Related]
66. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
[TBL] [Abstract][Full Text] [Related]
67. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
Ogura M; Imaizumi Y; Uike N; Asou N; Utsunomiya A; Uchida T; Aoki T; Tsukasaki K; Taguchi J; Choi I; Maruyama D; Nosaka K; Chen N; Midorikawa S; Ohtsu T; Tobinai K
Lancet Haematol; 2016 Mar; 3(3):e107-18. PubMed ID: 26947199
[TBL] [Abstract][Full Text] [Related]
68. [Agnogenic myelofibrosis].
Avilés A; Monroy L; Ambriz R; Butrón L; Pizzuto J
Gac Med Mex; 1981 Mar; 117(3):110-7. PubMed ID: 7327351
[No Abstract] [Full Text] [Related]
69. Anemia and hepatosplenomegaly as presenting features in a child with rickets and secondary myelofibrosis.
Gruner BA; DeNapoli TS; Elshihabi S; Britton HA; Langevin AM; Thomas PJ; Weitman SD
J Pediatr Hematol Oncol; 2003 Oct; 25(10):813-5. PubMed ID: 14528107
[TBL] [Abstract][Full Text] [Related]
70. Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.
Livun A; Newberry KJ; Manshouri T; Kusec R; Verstovsek S
Anticancer Res; 2015 Oct; 35(10):5219-23. PubMed ID: 26408680
[TBL] [Abstract][Full Text] [Related]
71. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
Lacout C; Pisani DF; Tulliez M; Gachelin FM; Vainchenker W; Villeval JL
Blood; 2006 Sep; 108(5):1652-60. PubMed ID: 16670266
[TBL] [Abstract][Full Text] [Related]
72. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
Tefferi A; Mesa RA; Nagorney DM; Schroeder G; Silverstein MN
Blood; 2000 Apr; 95(7):2226-33. PubMed ID: 10733489
[TBL] [Abstract][Full Text] [Related]
73. Agnogenic myeloid metaplasia in childhood: a report of two cases and efficiency of intravenous high dose methylprednisolone treatment.
Cetingül N; Yener E; Oztop S; Nisli G; Soydan S
Acta Paediatr Jpn; 1994 Dec; 36(6):697-700. PubMed ID: 7871986
[TBL] [Abstract][Full Text] [Related]
74. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
Guglielmelli P; Pancrazzi A; Bergamaschi G; Rosti V; Villani L; Antonioli E; Bosi A; Barosi G; Vannucchi AM; ;
Br J Haematol; 2007 May; 137(3):244-7. PubMed ID: 17408465
[TBL] [Abstract][Full Text] [Related]
75. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Mesa RA; Powell H; Lasho T; Dewald G; McClure R; Tefferi A
Leuk Res; 2006 Nov; 30(11):1457-60. PubMed ID: 16563504
[TBL] [Abstract][Full Text] [Related]
76. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
[TBL] [Abstract][Full Text] [Related]
77. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
Barosi G; Bergamaschi G; Marchetti M; Vannucchi AM; Guglielmelli P; Antonioli E; Massa M; Rosti V; Campanelli R; Villani L; Viarengo G; Gattoni E; Gerli G; Specchia G; Tinelli C; Rambaldi A; Barbui T;
Blood; 2007 Dec; 110(12):4030-6. PubMed ID: 17712047
[TBL] [Abstract][Full Text] [Related]
78. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
79. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
80. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
